•  
  •  
  •  
  •  

2026-05-21 05:57:52

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • GRSE Launches Next-Gen OPV: Crafted for Vigilance, Built for Victory
  • Muthoot Finance Ranked India's No. 1 Most Trusted Financial Services Brand for 10th Consecutive Year
  • Ampere Magnus G Max by Greaves Electric Mobility Wins 'Family Scooter of the Year' at Times Drive Auto Summit and Awards 2026
  • Eris delivers 11% yoy growth in Domestic Formulations with 37% EBIDTA margin in FY26
  • DevX - Standalone Revenue from Operations grew 34.3% YoY in FY26

Keywords Selected:  CSO

Stock Report

  • Wipro Launches Wipro AI-DC Solution to Accelerate Enterprise-Scale AI Adoption and Transform Customer Experience
  • Gland Pharma receives approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)
  • Alembic Pharmaceuticals Limited announces USFDA Final Approval for Travoprost Ophthalmic Solution USP, 0.004%
  • FDC Ltd receives USFDA approval for ANDA Pilocarpine Hydrochloride Ophthalmic Solutions
  • KFin Technologies Introduces New-Gen KYC Solution to Streamline Customer Onboarding
  • Gland Pharma receives approval from USFDA for Latanoprostene Bunod Opthalmic Solution
  • Parag Milk Foods Strengthens Leadership Commitment with Convertible Warrants Allotment to CSO Mr. Ankit Jain
  • DCM Shriram Limited commissions new caustic soda flakes plant
  • Glenmark receives ANDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2%
  • Caplin Steriles Ltd receives USFDA final approval for ANDA Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution
  • Alembic Pharmaceuticals Ltd announces USFDA Tentative Approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)
  • Gland Pharma receives approval for Latanoprost Opthalmic Solution, 0.005% (2.5 mL Fill)
  • Expansion of Smart Mobility Payment Solutions with Pilot of 'Ongo Ride' Instant NCMC Solution in Mumbai
  • Glenmark Pharmaceuticals Inc., USA launches Travoprost Ophthalmic Solution USP, 0.004%
  • Glenmark Therapeutics Inc., USA launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% OTC
  • Gland Pharma receives Tentative Approval from the USFDA for Latanoprostene Bunod Ophthalmic Solution
  • Alembic Pharmaceuticals announces USFDA Final Approval for Bromfenac Ophthalmic Solution, 0.07%
  • Futuristic Solutions Limited recommends final dividend of Rs. 1
  • Lupin receives approval from U.S. FDA for Travoprost Ophthalmic Solution USP
  • DCM Shriram Ltd commissions Caustic Soda Expansion Project
  • STL unveils US-made, 'Build America, Buy America' compliant fiber optic solutions
  • Caplin Steriles gets USFDA approval for Ofloxacin Ophthalmic Solution
  • Caplin Steriles gets USFDA approval for Ketorolac Tromethamine Ophthalmic Solution
  • 23-yr-old Chilean student wins 'World's Best Coder' title at TCS CodeVita 2024

Latest Post

  • GRSE Launches Next-Gen OPV: Crafted for Vigilance, Built for Victory
  • Muthoot Finance Ranked India's No. 1 Most Trusted Financial Services Brand for 10th Consecutive Year
  • Ampere Magnus G Max by Greaves Electric Mobility Wins 'Family Scooter of the Year' at Times Drive Auto Summit and Awards 2026
  • Eris delivers 11% yoy growth in Domestic Formulations with 37% EBIDTA margin in FY26
  • DevX - Standalone Revenue from Operations grew 34.3% YoY in FY26


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025